Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and the active ingredient in Wegovy, which is available in oral and subcutaneous formulations.[1] The clinical weight-management research summarized here examines defined groups of adults and specified treatment regimens, rather than every product sold under the ingredient name.[2] Its interpretation depends on the formulation, indication, accompanying care, and length of follow-up, including what happens when treatment stops.[2] This guide brings those benefit findings together with the product’s labeled safety information, interaction questions, and quality considerations so that a trial result remains connected to the circumstances in which it was obtained.
Benefits
In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[2] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[2] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[2] Gastrointestinal adverse effects were common, and the trial used a defined pharmaceutical formulation under clinical supervision.[2] Its results should not be generalized to every dose, route, or patient group.[2]
Safety
The Wegovy label lists common reactions including nausea, vomiting, diarrhea and constipation; serious warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury.[1] The thyroid-tumor warning comes from rodent findings whose relevance to humans is unknown.[1] The Medication Guide directs stopping treatment and seeking immediate help for persistent severe abdominal pain or serious allergic symptoms, including breathing difficulty or face/throat swelling.[1] Patients should disclose treatment before anesthesia or deep sedation because aspiration has been reported.[1]
Contraindications
The Wegovy label’s formal contraindications include personal/family medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and semaglutide/excipient hypersensitivity.[1] Separate pregnancy guidance for weight management directs discontinuation when pregnancy is recognized and at least two months before planned pregnancy.[1] Breastfeeding is not recommended with tablets; injection labeling calls for individualized assessment because milk-transfer and infant-effect data are missing.[1] Severe gastroparesis is a separate not-recommended precaution.[1]
Interactions
Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying may affect oral medicines, including those requiring close monitoring.[1] To evaluate an interaction, the evidence needs to address the substances together and describe the outcome being monitored. Separate studies cannot establish the combined effect, and an unanswered interaction question should remain an uncertainty rather than becoming reassurance. The relevant product information and clinical setting should guide interpretation of each specific concern.
Forms & dosing
Wegovy tablets and subcutaneous injections have separate escalation, maintenance, administration and switching instructions.[1] The amount administered is only one part of an intervention: formulation, route, frequency, treatment duration, and monitoring also define what was tested. Keeping those details attached to a result prevents a research schedule from being presented as a validated regimen for a different use. The same ingredient name does not establish equivalence between different preparations or indications.
Results & stopping
Wegovy is labeled for long-term weight maintenance; its Medication Guide directs clinician discussion after multiple missed weekly injections.[1] Weight regain was substantial after treatment ended in the STEP 1 extension.[3] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[3] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[3] It nevertheless shows that a successful treatment period does not guarantee permanent weight maintenance after withdrawal.[3]
Product quality
FDA identifies semaglutide sodium and acetate as different active ingredients from those in approved drugs and says their chemical and pharmacologic equivalence is not established.[4] The agency has also received reports of dosing errors with compounded semaglutide injections, including cases requiring hospitalization.[4] A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[5] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[5] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[5] The sample was small and selected, so it cannot estimate the failure rate of the entire market.[5] It does demonstrate why a seller's percentage or certificate cannot, by itself, establish that a finished injectable product is suitable for human use.[5]
Status
Wegovy has approved weight-management indications; eligibility and other indications differ between oral and injectable formulations.[1] Compounded semaglutide is not FDA-approved and does not undergo the agency's premarket review for safety, effectiveness and quality.[6] Regulatory status needs to be read for the exact substance, finished product, indication, and jurisdiction being discussed. A research publication, a supplier listing, and a regulatory decision answer different questions, so none should be used as a substitute for the others.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
| Human researchLarge double-blind randomized placebo-controlled trial.[2] In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[2] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[2] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[2] Main limitation: Average trial response does not predict an individual's result.[2] | ||
| Human researchObservational extension of a randomized trial.[3] Weight regain was substantial after treatment ended in the STEP 1 extension.[3] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[3] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[3] Main limitation: Selected follow-up subset; drug and lifestyle intervention both stopped.[3] | ||
| Product-testing researchSmall observational test-purchase and laboratory study.[5] A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[5] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[5] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[5] Main limitation: Documents failures; does not estimate market-wide prevalence.[5] |
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study
Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non‑randomized study
Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP‑1 receptor agonist, compared with placebo and open‑label semaglutide in people with type 2 diabetes: a randomised clinical trial
Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE
Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus
Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial
Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double‑blind, Phase IIIa, randomised trial
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double‑blind, Phase IIIa, randomised trial
Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH
High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial
Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach
Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes
Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial
Long-acting PYY336 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
Once‑weekly IcoSema versus once‑weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase IIb single-centred clinical trial
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
Oral semaglutide for Alcohol Use Disorder: A randomized clinical trial
Pharmacokinetics, Safety and Tolerability of Once- Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly
Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study
Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study
Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
evoke and evoke+: design of two largescale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
FAQs
How much weight loss did semaglutide produce in a major clinical trial?
In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[2] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[2] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[2] Gastrointestinal adverse effects were common, and the trial used a defined pharmaceutical formulation under clinical supervision.[2] Its results should not be generalized to every dose, route, or patient group.[2]
What happens to weight after stopping semaglutide?
Weight regain was substantial after treatment ended in the STEP 1 extension.[3] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[3] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[3] It nevertheless shows that a successful treatment period does not guarantee permanent weight maintenance after withdrawal.[3]
Does a 99% purity claim mean a peptide is safe to inject?
A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[5] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[5] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[5] The sample was small and selected, so it cannot estimate the failure rate of the entire market.[5] It does demonstrate why a seller's percentage or certificate cannot, by itself, establish that a finished injectable product is suitable for human use.[5]
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for Semaglutide.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
10 sources
- WEGOVY U.S. Prescribing Information, revised June 2026 (2026)Regulatory labelingSave study
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021)Primary researchReview status · PendingSave study
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022)Primary researchReview status · PendingSave study
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (Accessed 2026-10-03)Regulatory assessmentSave study
- Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases (2024)Primary researchReview status · PendingSave study
- FDA: Understanding the Risks of Compounded Drugs (Accessed 2026-10-03)Regulatory assessmentSave study
- Has anyone switched from Tirzepatide to Semaglutide? Less effective? More effective?
- Trying to decide between tirzepatide vs semaglutide anyone have real experience with both
- How to not regain it all back?
- Weight rebound after stopping
Selected public discussions help us choose questions. They are not clinical evidence. Explore discussions
